share_log

CVS Health | 8-K: Current report

CVS Health | 8-K: Current report

西維斯健康 | 8-K:重大事件
美股SEC公告 ·  12/02 22:55

Moomoo AI 已提取核心訊息

On December 2, 2024, CVS Health announced cash tender offers for its 4.100% Senior Notes due 2025 and other series of notes, including those issued by Aetna. The total purchase price for these offers will not exceed $2 billion, excluding accrued interest. The tender offers aim to retire a portion of CVS Health's outstanding debt.The Any and All Notes tender offer expires on December 6, 2024, while the Maximum Tender Offer Notes have an early tender date of December 13, 2024, and a final expiration date of December 31, 2024. CVS Health plans to fund these offers with proceeds from new subordinated debt securities.Barclays Capital Inc. and Mizuho Securities USA LLC are acting as Dealer Managers for the tender offers, with D.F. King & Co., Inc. as the Tender and Information Agent.
On December 2, 2024, CVS Health announced cash tender offers for its 4.100% Senior Notes due 2025 and other series of notes, including those issued by Aetna. The total purchase price for these offers will not exceed $2 billion, excluding accrued interest. The tender offers aim to retire a portion of CVS Health's outstanding debt.The Any and All Notes tender offer expires on December 6, 2024, while the Maximum Tender Offer Notes have an early tender date of December 13, 2024, and a final expiration date of December 31, 2024. CVS Health plans to fund these offers with proceeds from new subordinated debt securities.Barclays Capital Inc. and Mizuho Securities USA LLC are acting as Dealer Managers for the tender offers, with D.F. King & Co., Inc. as the Tender and Information Agent.
2024年12月2日,CVS Health宣佈了其2025年到期的4.100%優先票據和其他系列票據(包括安泰發行的票據)的現金要約。不包括應計利息,這些優惠的總購買價格不會超過20億美元。招標要約旨在償還CVS Health的部分未償債務。所有票據的要約將於2024年12月6日到期,而最高投標要約票據的提前投標日期爲2024年12月13日,最終到期日爲2024年12月31日。CVS Health計劃用新的次級債務證券的收益爲這些要約提供資金。巴克萊資本公司和瑞穗證券美國有限責任公司擔任要約的交易商經理,D.F. King & Co., Inc.擔任投標和信息代理人。
2024年12月2日,CVS Health宣佈了其2025年到期的4.100%優先票據和其他系列票據(包括安泰發行的票據)的現金要約。不包括應計利息,這些優惠的總購買價格不會超過20億美元。招標要約旨在償還CVS Health的部分未償債務。所有票據的要約將於2024年12月6日到期,而最高投標要約票據的提前投標日期爲2024年12月13日,最終到期日爲2024年12月31日。CVS Health計劃用新的次級債務證券的收益爲這些要約提供資金。巴克萊資本公司和瑞穗證券美國有限責任公司擔任要約的交易商經理,D.F. King & Co., Inc.擔任投標和信息代理人。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息